Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Cell Immunol. 2017 Jul 10;319:28–34. doi: 10.1016/j.cellimm.2017.07.002

Figure 2. CD28 mutations augment T cell proliferation.

Figure 2

A) Splenocytes from CD28-deficient OVA TCR transgenic mice were transduced with either empty vector (RV), wild type or mutant CD28 constructs and stimulated with OVA peptide in the presence of autologous APC and proliferation determined by tritiated thymidine incorporation. Shown are the mean and standard deviation of triplicate wells. ** indicates p < .001 by 2-tailed unpaired T-test with adjustment for multiple comparisons for all 3 mutant constructs compared to WT CD28 and for WT CD28 as compared to RV at OVA doses from .03 μM to 1.0 μM OVA. B) Retrovirally transduced CD28-deficient splenocytes were stimulated with OVA alone (0.3 μM) alone or with the addition of anti-CD28 antibody (1.0 μg/ml), both in the presence of autologous APC and proliferation measured. All results shown are representative results from 3–5 independent experiments. Statistical significance was determined by a 2-tailed unpaired T-test with multiple comparisons.